期刊文献+

NO、ET-1及ADMA与血液透析高血压的相关性研究

下载PDF
导出
摘要 目的探讨维持性血液透析(MHD)患者血清一氧化氮(NO)、内皮素-1(ET-1)、及不对称二甲基精氨酸(ADMA)与血液透析高血压的相关性。方法检测MHD患者血透前后NO、ET-1及ADMA水平,与血透前后的MAP进行相关性分析。结果 MHD组MAP明显高于健康对照组(P<0.01),透析高血压发生率为28.3%。MHD患者血透后NO水平显著下降。按血透前后MAP变化分组后,血压升高组透析后ET-1水平较透前显著升高,而血压平稳组ET-1水平也较透前略有升高,但差别无统计学意义,2组透后NO水平均下降,ADMA水平变化均不显著。χ2检验结果显示,血液透析前后ET-1水平的变化对MAP的变化有影响作用(P<0.05),血液透析前后ET-1水平变化与MAP变化有相关性,呈正相关(r=0.434,P<0.01),多元线性回归方程为y=1.722+0.297x(回归系数经t检验,P=<0.05)。结论 (1)MHD患者血液透析高血压的发生率较高。(2)透析后ET-1水平升高可能是引发血液透析高血压的重要因素。(3)虽然透析后NO的浓度下降,但对MAP的影响不大,因此,可能不是引起透析后血压变化的重要因素。
出处 《中外医疗》 2011年第10期68-70,共3页 China & Foreign Medical Treatment
  • 相关文献

参考文献12

  • 1Amerling RCG,Dubrow A,Levin N,et al.Complications during hemodialysis.In:Nissenson A,Gentile D,eds.Clinical Dialysis[J].Stamford,CT:Appleton & Lange,1995:236-267.
  • 2Chen J,Gul A,Sarnak MJ.Managernent of intradialytic hypertension:The ongoing challenge[J].Semin Dial,2006,19(2):141-145.
  • 3Zager PG,Nikolie J,Brown RH,et al."U"curve association of blood pressure and mortality in hemodialysis patients.Medical Directors of Dialysis Clinic,Inc[J].Kidney Int,1998,54(2):561-569.
  • 4贾凤玉,孟建中.终末期肾衰维持性血液透析患者高血压发生原因分析及对策[J].山东医药,2009,49(39):117-118. 被引量:12
  • 5Lowensfein CG,Dineman JL,Synder SH.Nitric Oxide:a physiologic messenger[J].Am Intern Med,1994,120:227.
  • 6乔青,魏翠英,佟光明,王彩丽.血液透析对尿毒症患者血清内皮素-1、一氧化氮、血管紧张素Ⅱ的影响及临床意义[J].中国医药导刊,2004,6(6):405-406. 被引量:7
  • 7丁红香,楼文文,张信良,李向阳,毛朝鸣.维持性血液透析患者血浆一氧化氮和内皮素的变化[J].浙江临床医学,2001,3(4):231-232. 被引量:3
  • 8Miyauchi T,Suzuki N.Endothelin-1 and endothelin-3 play different roles in acute and chronic alterations of blood pressure with chronic hemodialysis[J].Biochem Biophys Res Commun,1991,178(1):276.
  • 9Dominic S C,Raj M D.Hemodynamic changes during hemodialysis:Role of nitric oxide and endothelin[J].Kidney International,2002,61:697-704.
  • 10Wahbi N,Dalton RN.Dimethylarginines in chronic renal failure[J].J Clin Pathol,2001,54:470-473.

二级参考文献26

  • 1Cirit M, Akcicek F, Terzioglu E, et al. "Paradoxical" rise in blood pressure during ultrafiltration in dialysis patients[ J]. Nephrol Dial Transplant, 1995,10 ( 8 ) : 1417-1420.
  • 2Khosla UM, Johnson RJ. Hypertension in the hemodialysis patient and the"lag phenomenon" : insights into pathophysiology and clinical management[ J]. Am J Kidney Dis,2004,43(4) :739-751.
  • 3Grekas D, Kalevrosoglou I, Karamouzis M, et al. Effect of sympathetic and plasma renin activity on hemodialysis hypertension [ J ]. Clin Nephrol, 2001,55(2) :115-120.
  • 4Xu JC, Li GY, Wang PL, Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure[ J]. J Clin Invest,2005,115(5) :1275-1280.
  • 5Kaupke CJ , Kim S , Vaziri ND. Effect of erythrocyte mass of arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy[ J]. J Am Soc Nephrol, 1994,4( 11 ) : 1874-1878.
  • 6Morris ST, Jardine AG. The vascular endothelium in chronicrenal failure[ J]. Nephrol,2000,13 (2) :96-105.
  • 7Charra B,Chazot C,Jean G,et al. Long 3 ×8 hr dialysis:a three decade summary[ J]. Nephrology, 2003,16 ( suppl 7) : S64-S69.
  • 8LuikAJ,Sande FM,Weideman P,et al. The influence of increasing dialysis treatment time and reducing dryweight on bloodpressure control in hemodialysis patients: a prospective study [ J ]. Am J Nephrol,2001,21 (6) :471-478.
  • 9Fagugli RM, Pasin P, Pasticci F, et al. Effects of short daily hemo dialysis an dextcnded standard hemodialysis on bloodpressure and cardiac hypertrophy : acomparative study [ J ]. J Nephrol, 2006,19 ( 1 ) :77-83.
  • 10Nesrallah GE ,Moist LM, Awaxaji C, el al. An international registry to compare quotidian dialysis regimens with conventional thrice weekly hemodialysis : why, how, and potential pitfalls [ J ]. Semin Dial,2004,17 (2) :131-135.

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部